[ACCESSWIRE]
LAS VEGAS, NV / ACCESSWIRE / May 20, 2016 / As summer approaches, the weather continues getting hotter across the country and these 6 biotechnology companies could help investors surf a wave of profits from June to August.
For instance, one stock with a bright near term future is Endonovo Therapeutics (OTCQB: ENDV). This innovative biotech company focuses on bioelectronic medicine with a concentration on treating inflammatory conditions in vital organs. ENDV's Immunotronics platform is a non-implantable bio-electronic device for treating and preventing vital organ failure by reducing inflammation. ENDV's Cytotronics platform uses bioelectronics to expand and enhance the therapeutic potential of stem cells. Endonovo is using its Cytotronics platform to develop a cell therapy for treating Graft-Versus-Host Disease (GvHD), producing fully human biologics from adult stem cells and for expanding the use of low volume cord blood units.
Endonovo Therapeutics, Inc. (ENDV)'s 2016 has been extremely volatile. The stock's year to date low bottomed at $0.25 while its high peaked at $0.81thus representing a 224% spread. The peaks and valleys have given investors amazing profit opportunities all the while giving the stock a large market. So far the stock has made 3 major moves in 2016; a 196% jolt from $0.25 to $0.74, a 100% pop from $0.27 to $0.54, and a 118% run from $0.37 to $0.81.
Each of these major runs has come after a consolidation period around the stocks bottom stages ($0.24, $0.27, $0.37). It appears ENDV has consolidated around $0.45, meaning we could be on the verge of ENDV's next triple digit run.
There are fundamental reasons to believe that now is the time for an ENDV breakout beyond its amazing technicals.
The company is set to present at the SeeThruEquity Microcap Investor Conference on May 31st and at the Marcum Microcap Conference on June 2 in NYC, with investors learning about ENDV at this conference coming away impressed.
Three major factors investors will see as positive indicators for ENDV's long term viability include:
- In April, Endonovo provided a corporate update in which it indicated the buyback of $154,303 in convertible notes, in an attempt to preserve shareholder value as well as position the company to attract institutional investors.
- On March 30, Endonovo announced that it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application entitled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells." The patent application covers the production of biological molecules in adult stem cells, which can be used to produce human proteins. The Notice of Allowance indicates that the company could receive a US patent in the near future. Going by CEO Alan Collier's comments, Endonovo may license this technology or partner with a larger pharmaceutical company to develop it.
- In February, Endonovo announced that it was preparing to file paperwork to obtain an orphan drug designation for its treatment of Graft-Versus-Host Disease. If approved as an orphan drug by the FDA, it would entitle the company to a 7-year period of marketing exclusivity in the US for the treatment of Graft-Versus-Host Disease (GVHD).
Galena Biopharma, Inc. (GALE) has also had a volatile 2016, after falling 57% to begin the year the stock rebounded from its 63 cent low, from there it made a 177% rally. The company is still up 104% from its 2016 lows, and has been consolidating in its current price range. Following last week's conference call, we could see GALE pick a direction for its next major price movement this week. Monitor closely.
Vitae Pharmaceuticals, Inc. (VTAE) has been stuck in a trading channel between $6 and $8 since mid March. The stock is on the lower end of the channel with some bullish momentum, VTAE could make investors at this range very happy.
Athersys, Inc. (ATHX) quarterly profit came in far ahead of expectations for the fourth quarter, showing a gain of $0.06 per share, while analysts were expecting a loss of $0.08 per share. This has caused the share price to double. Friday, the company released even better numbers for the first quarter of 2016, expect ATHX to have a big week.
BioCryst Pharmaceuticals, Inc. (BCRX) on the other hand reported underwhelming results for Q1, killing the bullish momentum the stock began building after submarining from $6 a share to $2 in February. Still this is a company that was trading over $9 a year ago, and there seems to be strong support around $2. This could be an excellent entry level for patient investors that believe in the company.
OncoMed Pharmaceuticals, Inc. (OMED) has had a very similar 2016 to BCRX as far as price movement goes. Investors saw this stock rally in a big way on Friday making it one of the Russell 2000's biggest movers for May 13th. Investors are left wondering if this could be the start of a breakout many have been hoping to see in 2016.
If you are looking for larger upside, then it may be wise to lean toward the more volatile of these companies, Endonovo Therapeutics, Inc.. Of the 6 securities, ENDV, looks to be the most likely to earn investors massive profits in the near term.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC., which owns Microcapspeculators.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC., which owns Microcapspeculators.com, may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated a total of $28,000 cash by a non-affiliate third party of ENDV.
Contact:
[email protected]
SOURCE: ACR Communication, LLC
